BeOne Medicines (ONC)

NASDAQ:ONC

ONC

BeOne Medicines

RESEARCH TOOLSreports

BeOne Medicines (ONC) Stock Forecast & Price Target

859 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ONC Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

BeOne

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$400.27

▲(28.79% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $400.27 with a high forecast of $425.00 and a low forecast of $340.00. The average price target represents a 28.79% change from the last price of $310.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"244":"$244","335":"$335","426":"$426","289.5":"$289.5","380.5":"$380.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$425.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":400.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$400.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$340.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[244,289.5,335,380.5,426],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,317.40615384615387,326.3723076923077,335.33846153846156,344.3046153846154,353.27076923076925,362.23692307692306,371.20307692307694,380.16923076923075,389.1353846153846,398.10153846153844,407.0676923076923,416.0338461538462,{"y":425,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,315.50384615384615,322.5676923076923,329.63153846153847,336.6953846153846,343.7592307692308,350.8230769230769,357.88692307692304,364.9507692307692,372.01461538461535,379.0784615384615,386.14230769230767,393.2061538461538,{"y":400.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,310.8676923076923,313.2953846153846,315.7230769230769,318.15076923076924,320.5784615384615,323.00615384615384,325.43384615384616,327.8615384615385,330.28923076923076,332.7169230769231,335.1446153846154,337.5723076923077,{"y":340,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":345,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$425.00

Average Price Target$400.27

Lowest Price Target$340.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kalpit Patel

Wolfe Research

$340

Buy

9.40%

Upside

Initiated

03/26/26

Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones

Etzer Darout

Barclays

$405

Buy

30.31%

Upside

Reiterated

03/18/26

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

Rebecca Liang

Bernstein

$412

Buy

32.57%

Upside

Reiterated

03/18/26

Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), Argenx Se (NASDAQ: ARGX) and Erasca (NASDAQ: ERAS)

Jill Wu

CMB International Securities

$392.43

Buy

26.27%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Sean Laaman

Morgan Stanley

$405→$389

Buy

25.16%

Upside

Reiterated

02/27/26

BeOne Medicines (ONC) Gets a Buy from Morgan Stanley

Michael Schmidt

Guggenheim

$400→$410

Buy

31.92%

Upside

Reiterated

02/26/26

Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)

Yaron Werber

TD Cowen

$424

Buy

36.43%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and BeOne Medicines (NASDAQ: ONC)

Leonid Timashev

RBC Capital

$417→$425

Buy

36.75%

Upside

Reiterated

02/26/26

BeOne Medicines (ONC) Receives a Buy from RBC Capital

Yigal Nochomovitz

Citi

$405

Buy

30.31%

Upside

Reiterated

01/13/26

Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)

Clara Dong

Jefferies

$420

Buy

35.14%

Upside

Reiterated

11/25/25

Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$389→$402.2

Buy

29.41%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Reni Benjamin

Citizens JMP

$348→$396

Buy

27.42%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP

Jessica Fye

J.P. Morgan

$345→$385

Buy

23.88%

Upside

Reiterated

10/08/25

BeOne Medicines (ONC) Receives a Buy from J.P. Morgan

Andrew Berens

Leerink Partners

$334→$345

Buy

11.01%

Upside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kalpit Patel

Wolfe Research

$340

Buy

9.40%

Upside

Initiated

03/26/26

Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones

Etzer Darout

Barclays

$405

Buy

30.31%

Upside

Reiterated

03/18/26

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

Rebecca Liang

Bernstein

$412

Buy

32.57%

Upside

Reiterated

03/18/26

Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), Argenx Se (NASDAQ: ARGX) and Erasca (NASDAQ: ERAS)

Jill Wu

CMB International Securities

$392.43

Buy

26.27%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Sean Laaman

Morgan Stanley

$405→$389

Buy

25.16%

Upside

Reiterated

02/27/26

BeOne Medicines (ONC) Gets a Buy from Morgan Stanley

Michael Schmidt

Guggenheim

$400→$410

Buy

31.92%

Upside

Reiterated

02/26/26

Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)

Yaron Werber

TD Cowen

$424

Buy

36.43%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and BeOne Medicines (NASDAQ: ONC)

Leonid Timashev

RBC Capital

$417→$425

Buy

36.75%

Upside

Reiterated

02/26/26

BeOne Medicines (ONC) Receives a Buy from RBC Capital

Yigal Nochomovitz

Citi

$405

Buy

30.31%

Upside

Reiterated

01/13/26

Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)

Clara Dong

Jefferies

$420

Buy

35.14%

Upside

Reiterated

11/25/25

Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$389→$402.2

Buy

29.41%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Reni Benjamin

Citizens JMP

$348→$396

Buy

27.42%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP

Jessica Fye

J.P. Morgan

$345→$385

Buy

23.88%

Upside

Reiterated

10/08/25

BeOne Medicines (ONC) Receives a Buy from J.P. Morgan

Andrew Berens

Leerink Partners

$334→$345

Buy

11.01%

Upside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months

xxx

Success Rate

6/9 ratings generated profit

Average Return

+6.18%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.18% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

29/35 ratings generated profit

Average Return

+37.53%

reiterated a buy rating last month

Copying Yaron Werber's trades and holding each position for 1 Year would result in 82.86% of your transactions generating a profit, with an average return of +37.53% per trade.

2 Years

xxx

Success Rate

8/10 ratings generated profit

Average Return

+39.67%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +39.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ONC has received 43 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 400.27.

Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $1.01 with a range of $0.29 to $2.22. The previous quarter’s EPS was $0.60. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.44B with a range of $1.34B to $1.54B. The previous quarter’s sales results were $1.50B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?

Based on analyst ratings, BeOne Medicines’s 12-month average price target is 400.27.

What is ONC’s upside potential, based on the analysts’ average price target?

BeOne Medicines has 28.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ONC a Buy, Sell or Hold?

BeOne Medicines has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is BeOne Medicines’s price target?

The average price target for BeOne Medicines is 400.27. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $425.00 ,the lowest forecast is $340.00. The average price target represents 28.79% Increase from the current price of $310.79.

What do analysts say about BeOne Medicines?

BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ONC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BeOne Medicines (ONC) Stock Forecast & Price Target

ONC Analyst Ratings

ONC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BeOne Medicines

ONC Analyst Recommendation Trends

ONC Financial Forecast

ONC Earnings Forecast

ONC Sales Forecast

ONC Stock Forecast FAQ

Detailed List of Analyst Forecasts